[1]
|
Mcmurray, J.J., Adamopoulos, S., Anker, S.D., et al. (2012) ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in Collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 14, 803-869. https://doi.org/10.1093/eurjhf/hfs105
|
[2]
|
Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2013) 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62, e147-e239.
https://doi.org/10.1161/CIR.0b013e31829e8776
|
[3]
|
Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure: The Task Force for the Di-agnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) Developed with the Special Contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37, 2129-2200. https://doi.org/10.1093/eurheartj/ehw128
|
[4]
|
Wang, H., Chai, K., Du, M., et al. (2021) Prevalence and Incidence of Heart Failure among Urban Patients in China: A National Population-Based Analysis. Circulation Heart Failure, 14, e008406.
https://doi.org/10.1161/CIRCHEARTFAILURE.121.008406
|
[5]
|
Cheng, R.K., Cox, M., Neely, M.L., et al. (2014) Outcomes in Patients with Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction in the Medicare Pop-ulation. American Heart Journal, 168, 721-730.
https://doi.org/10.1016/j.ahj.2014.07.008
|
[6]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., et al. (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiolo-gy/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
|
[7]
|
Shah, S.J., Katz, D.H., Selvaraj, S., et al. (2015) Phenomap-ping for Novel Classification of Heart Failure with Preserved Ejection Fraction. Circulation, 131, 269-279. https://doi.org/10.1161/CIRCULATIONAHA.114.010637
|
[8]
|
Kao, D.P., Lewsey, J.D., Anand, I.S., et al. (2015) Characterization of Subgroups of Heart Failure Patients with Preserved Ejection Fraction with Possible Implications for Prognosis and Treatment Response. European Journal of Heart Failure, 17, 925-935. https://doi.org/10.1002/ejhf.327
|
[9]
|
Persoon, S., Paulus, M., Hirt, S., et al. (2018) Cardiac Unloading by LVAD Support Differentially Influences Components of the cGMP-PKG Signaling Pathway in Ischemic and Dilated Cardio-myopathy. Heart and Vessels, 33, 948-957.
https://doi.org/10.1007/s00380-018-1149-x
|
[10]
|
Shyu, K.G. (2017) The Role of Endoglin in Myocardial Fibrosis. Acta Cardiologica Sinica, 33, 461-467.
|
[11]
|
Mishra, S. and Kass, D.A. (2021) Cellular and Molecular Pathobiology of Heart Failure with Preserved Ejection Fraction. Nature Reviews Cardiology, 18, 400-423. https://doi.org/10.1038/s41569-020-00480-6
|
[12]
|
Steinberg, B.A., Zhao, X., Heidenreich, P.A., et al. (2012) Trends in Patients Hospitalized with Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Thera-pies, and Outcomes. Circulation, 126, 65-75.
https://doi.org/10.1161/CIRCULATIONAHA.111.080770
|
[13]
|
Kenchaiah, S., Evans, J.C., Levy, D., et al. (2002) Obesity and the Risk of Heart Failure. The New England Journal of Medicine, 347, 305-313. https://doi.org/10.1056/NEJMoa020245
|
[14]
|
Ward, Z.J., Bleich, S.N., Cradock, A.L., et al. (2019) Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. The New England Journal of Medicine, 381, 2440-2450. https://doi.org/10.1056/NEJMsa1909301
|
[15]
|
Sharma, K. and Kass, D.A. (2014) Heart Failure with Preserved Ejection Fraction: Mechanisms, Clinical Features, and Therapies. Circulation Research, 115, 79-96. https://doi.org/10.1161/CIRCRESAHA.115.302922
|
[16]
|
Ho, J.E., Lyass, A., Lee, D.S., et al. (2013) Predictors of New-Onset Heart Failure: Differences in Preserved versus Reduced Ejection Fraction. Circulation Heart Failure, 6, 279-286.
https://doi.org/10.1161/CIRCHEARTFAILURE.112.972828
|
[17]
|
Savji, N., Meijers, W.C., Bartz, T.M., et al. (2018) The Association of Obesity and Cardiometabolic Traits with Incident HFpEF and HFrEF. JACC Heart Failure, 6, 701-709. https://doi.org/10.1016/j.jchf.2018.05.018
|
[18]
|
Kitzman, D.W. and Shah, S.J. (2016) The HFpEF Obesity Phenotype: The Elephant in the Room. Journal of the American College of Cardiology, 68, 200-203. https://doi.org/10.1016/j.jacc.2016.05.019
|
[19]
|
Obokata, M., Reddy, Y.N.V., Pislaru, S.V., et al. (2017) Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction. Circulation, 136, 6-19.
https://doi.org/10.1161/CIRCULATIONAHA.116.026807
|
[20]
|
Bays, H.E., González-Campoy, J.M., Bray, G.A., et al. (2008) Pathogenic Potential of Adipose Tissue and Metabolic Consequences of Adipocyte Hypertrophy and In-creased Visceral Adiposity. Expert Review of Cardiovascular Therapy, 6, 343-368. https://doi.org/10.1586/14779072.6.3.343
|
[21]
|
Rao, V.N., Zhao, D., Allison, M.A., et al. (2018) Adiposity and In-cident Heart Failure and Its Subtypes: MESA (Multi-Ethnic Study of Atherosclerosis). JACC Heart Failure, 6, 999-1007. https://doi.org/10.1016/j.jchf.2018.07.009
|
[22]
|
Bays, H.E. (2011) Adiposopathy Is “Sick Fat” a Cardiovascular Disease? Journal of the American College of Cardiology, 57, 2461-2473. https://doi.org/10.1016/j.jacc.2011.02.038
|
[23]
|
Berg, G., Miksztowicz, V., Morales, C., et al. (2019) Epicardial Adipose Tissue in Cardiovascular Disease. Advances in Experimental Medicine and Biology, 1127, 131-143. https://doi.org/10.1007/978-3-030-11488-6_9
|
[24]
|
Fitzgibbons, T.P. and Czech, M.P. (2014) Epicardial and Peri-vascular Adipose Tissues and Their Influence on Cardiovascular Disease: Basic Mechanisms and Clinical Associations. Journal of the American Heart Association, 3, e000582. https://doi.org/10.1161/JAHA.113.000582
|
[25]
|
Paulus, W.J. and Tschöpe, C. (2013) A Novel Paradigm for Heart Failure with Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling through Coronary Microvascular Endothelial Inflammation. Journal of the American College of Cardiology, 62, 263-271. https://doi.org/10.1016/j.jacc.2013.02.092
|
[26]
|
Chien, S.C., Chandramouli, C., Lo, C.I., et al. (2021) Associations of Obesity and Malnutrition with Cardiac Remodeling and Cardi-ovascular Outcomes in Asian Adults: A Cohort Study. PLoS Medicine, 18, e1003661.
https://doi.org/10.1371/journal.pmed.1003661
|
[27]
|
Jamaly, S., Carlsson, L., Peltonen, M., et al. (2019) Surgical Obesity Treatment and the Risk of Heart Failure. European Heart Journal, 40, 2131-2138. https://doi.org/10.1093/eurheartj/ehz295
|
[28]
|
Reddy, Y.N.V., Obokata, M., Verbrugge, F.H., et al. (2020) Atrial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation. Journal of the Ameri-can College of Cardiology, 76, 1051-1064.
https://doi.org/10.1016/j.jacc.2020.07.009
|
[29]
|
Lam, C.S. and Lund, L.H. (2016) Microvascular Endothelial Dys-function in Heart Failure with Preserved Ejection Fraction. Heart (British Cardiac Society), 102, 257-259. https://doi.org/10.1136/heartjnl-2015-308852
|
[30]
|
Brouwers, F.P., De Boer, R.A., Van Der Harst, P., et al. (2013) Incidence and Epidemiology of New Onset Heart Failure with Preserved vs. Reduced Ejection Fraction in a Communi-ty-Based Cohort: 11-Year Follow-Up of PREVEND. European Heart Journal, 34, 1424-1431. https://doi.org/10.1093/eurheartj/eht066
|
[31]
|
Paulus, W.J. and Zile, M.R. (2021) From Systemic Inflammation to Myocardial Fibrosis: The Heart Failure with Preserved Ejection Fraction Paradigm Revisited. Circulation Research, 128, 1451-1467.
https://doi.org/10.1161/CIRCRESAHA.121.318159
|
[32]
|
Zelnick, L.R., Katz, R., Young, B.A., et al. (2017) Echo-cardiographic Measures and Estimated GFR Decline among African Americans: The Jackson Heart Study. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 70, 199-206. https://doi.org/10.1053/j.ajkd.2016.11.022
|
[33]
|
Ravera, M., Noberasco, G., Signori, A., et al. (2013) Left-Ventricular Hypertrophy and Renal Outcome in Hypertensive Patients in Primary-Care. American Journal of Hy-pertension, 26, 700-707. https://doi.org/10.1093/ajh/hps100
|
[34]
|
Agrawal, A., Naranjo, M., Kanjanahattakij, N., et al. (2019) Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction—An Under-Recognized Clinical En-tity. Heart Failure Reviews, 24, 421-437.
https://doi.org/10.1007/s10741-018-09768-9
|
[35]
|
Klein, D.A., Katz, D.H., Beussink-Nelson, L., et al. (2015) As-sociation of Chronic Kidney Disease with Chronotropic Incompetence in Heart Failure with Preserved Ejection Fraction. The American Journal of Cardiology, 116, 1093-1100.
https://doi.org/10.1016/j.amjcard.2015.06.038
|
[36]
|
Mihai, S., Codrici, E., Popescu, I.D., et al. (2018) Inflamma-tion-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. Journal of Immunology Re-search, 2018, Article ID: 2180373.
https://doi.org/10.1155/2018/2180373
|
[37]
|
Upadhya, B., Amjad, A. and Stacey, R.B. (2020) Optimizing the Man-agement of Obese HFpEF Phenotype: Can We Mind both the Heart and the Kidney? Journal of Cardiac Failure, 26, 108-111.
https://doi.org/10.1016/j.cardfail.2019.11.018
|
[38]
|
Faul, C., Amaral, A.P., Oskouei, B., et al. (2011) FGF23 In-duces Left Ventricular Hypertrophy. The Journal of Clinical Investigation, 121, 4393-4408. https://doi.org/10.1172/JCI46122
|
[39]
|
Neumann, J., Ligtenberg, G., Klein, I.I., et al. (2004) Sympathetic Hyperac-tivity in Chronic Kidney Disease: Pathogenesis, Clinical Relevance, and Treatment. Kidney International, 65, 1568-1576.
https://doi.org/10.1111/j.1523-1755.2004.00552.x
|
[40]
|
Rieger, A.C., Bagno, L.L., Salerno, A., et al. (2021) Growth Hormone-Releasing Hormone Agonists Ameliorate Chronic Kidney Disease-Induced Heart Failure with Pre-served Ejection Fraction. Proceedings of the National Academy of Sciences of the United States of America, 118, e2019835118. https://doi.org/10.1073/pnas.2019835118
|
[41]
|
Hickson, L.J., Negrotto, S.M., Onuigbo, M., et al. (2016) Echocardiography Criteria for Structural Heart Disease in Patients with End-Stage Renal Disease Initiating Hemo-dialysis. Journal of the American College of Cardiology, 67, 1173-1182. https://doi.org/10.1016/j.jacc.2015.12.052
|
[42]
|
Echouffo-Tcheugui, J.B., Xu, H., Devore, A.D., et al. (2016) Temporal Trends and Factors Associated with Diabetes Mellitus among Patients Hospitalized with Heart Failure: Find-ings from Get with the Guidelines-Heart Failure Registry. American Heart Journal, 182, 9-20. https://doi.org/10.1016/j.ahj.2016.07.025
|
[43]
|
Thorp, A.A. and Schlaich, M.P. (2015) Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome. Journal of Diabetes Research, 2015, Article ID: 341583. https://doi.org/10.1155/2015/341583
|
[44]
|
Heerspink, H.J., Perkins, B.A., Fitchett, D.H., et al. (2016) So-dium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Po-tential Mechanisms, and Clinical Applications. Circulation, 134, 752-772. https://doi.org/10.1161/CIRCULATIONAHA.116.021887
|
[45]
|
Dei Cas, A., Khan, S.S., Butler, J., et al. (2015) Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients with Heart Failure. JACC Heart Failure, 3, 136-145. https://doi.org/10.1016/j.jchf.2014.08.004
|
[46]
|
Vaishnav, J., Yanek, L.R., Hahn, V.S., et al. (2022) Un-der-Enrollment of Obese Heart Failure with Preserved Ejection Fraction Patients in Major HFpEF Clinical Trials. Journal of Cardiac Failure, 28, 723-731.
https://doi.org/10.1016/j.cardfail.2021.12.007
|
[47]
|
Faselis, C., Arundel, C., Patel, S., et al. (2020) Loop Diuretic Prescription and 30-Day Outcomes in Older Patients with Heart Failure. Journal of the American College of Cardiology, 76, 669-679. https://doi.org/10.1016/j.jacc.2020.06.022
|
[48]
|
Butler, J., Filippatos, G., Jamal Siddiqi, T., et al. (2022) Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 145, 184-193.
https://doi.org/10.1161/CIRCULATIONAHA.121.057812
|
[49]
|
Withaar, C., Meems, L.M.G., Markousis-Mavrogenis, G., et al. (2021) The Effects of Liraglutide and Dapagliflozin on Cardiac Function and Structure in a Multi-Hit Mouse Model of Heart Failure with Preserved Ejection Fraction. Cardiovascular Research, 117, 2108-2124. https://doi.org/10.1093/cvr/cvaa256
|
[50]
|
Tridetti, J., Nguyen Trung, M.L., Ancion, A., et al. (2020) The PARAGON-HF Trial. Revue Medicale de Liege, 75, 130-135.
|
[51]
|
Pieske, B., Maggioni, A.P., Lam, C.S.P., et al. (2017) Vericiguat in Patients with Worsening Chronic Heart Failure and Preserved Ejection Fraction: Results of the Sol-uble Guanylate Cyclase Stimulator in Heart Failure Patients with Preserved EF (Socrates-Preserved) Study. European Heart Journal, 38, 1119-1127.
https://doi.org/10.1093/eurheartj/ehw593
|